6,658 press releases indexed under healthcare.
New program combines patient education with affordable, in-home medication disposal to help reduce the risks of unused medications in the home. SOUTHERN PINES, N.C., Aug. 28, 2026 /PRNewswire/ -- DisposeRx®, the leader of in-home medication disposal, today announced a new partnership with...
SS Innovation’s SSi Mantra system was used in more than 50 robotic surgeries in a single day at Mohak Bariatrics and Robotics in Indore, highlighting growing clinical utilization in India. The milestone comes as SS Innovations reports 224 SSi Mantra systems installed across 12 countries, providing a growing installed base for future procedure and instrument revenue. Second-quarter 2026 installations reached 30 systems, above the 25 systems modeled by the analyst cited in the supplied report. Quarterly revenue reached $13.9 million, up 39% year over year, while system sales increased 41% to $12.4 million. FDA review of the SSi Mantra 510(k) application is now expected by the end of the first quarter of 2027, while European CE marking remains targeted for the end of 2026. The company’s progr
FDA determines JUUL2 System meets statutory standard of being "appropriate for the protection of public health" JUUL2 System incorporates a suite of innovative technology to better serve adults who smoke WASHINGTON, Aug. 28, 2026 /PRNewswire/ -- Yesterday, the U.S. Food and Drug...
PDA announced today that senior leaders from the FDA's centers for drugs, biologics and veterinary medicine as well as the Office of Inspections and Investigations will participate in the plenary on Monday, Sept. 14, as part of the 2026 PDA/FDA Joint Regulatory Conference in Washington, D....
VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate (“AOC”) developed through their research alliance. The AOC candidate demonstrated greater potency than the equivalent unconjugated oligonucleotide in early testing, providing a first experimental validation of the collaboration. AOCs are an emerging class of antibody-guided therapies designed to use an antibody to deliver therapeutic oligonucleotides selectively to disease-relevant cells. VERAXA contributes antibody conjugation expertise and proprietary click chemistry, allowing it to participate in AOCs without shifting its core oncology strategy. The collaboration adds to VERAXA’s growing partnering track record, which also includes its bispecific ADC di
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today...
Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue. Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach through GelrinC, a cell-free, off-the-shelf implant designed to support the regeneration of damaged knee cartilage. With encouraging clinical results, European approval and an ongoing U.S. pivotal trial, GelrinC is advancing toward a potential new approach to cartilage repair. LOS ANGELES, CA - August 28, 2026 ( NEWMEDIAWIRE ) - Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? One company pursuing a regenerative approach is Regentis B
OLDWICK, N.J., August 28, 2026--AM Best has affirmed the Long-Term Issuer Credit Rating (Long-Term ICR) of "a-" (Excellent) and the Long and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of UnitedHealth Group Incorporated (UnitedHealth Group) (Minnetonka, MN) [NYSE: UNH]. Concurrently AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term ICRs of "a+" (Excellent) of the health and dental insurance subsidiaries of UnitedHealth Group, collective
LINCOLN, Neb., Aug. 28, 2026 /PRNewswire/ -- The Dr. Steven Shannon Scholarship for Medical Students is accepting applications from undergraduate students across the United States who are preparing for careers in medicine and related healthcare fields. The one-time scholarship opportunity...
FDA found no factors that could explain the cause of the outbreak in ByHeart facilities FDA responded with no further questions on ByHeart's investigation and Action Plan ByHeart introduces new C. botulinum testing protocols 1000x more sensitive than the standard industry test methodology...
Experienced medical device executive to lead the company through its next phase of clinical, regulatory and strategic development CINCINNATI, Aug. 28, 2026 /PRNewswire/ -- Sense Neuro Diagnostics, a medical technology company developing a novel, non-invasive platform designed to rapidly...
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 28, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed ..